Insider Buying: Precision BioSciences, Inc. (NASDAQ:DTIL) Director Purchases 3,250 Shares of Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno J. Germano purchased 3,250 shares of the business’s stock in a transaction on Tuesday, March 25th. The shares were purchased at an average cost of $5.30 per share, for a total transaction of $17,225.00. Following the transaction, the director now directly owns 11,057 shares of the company’s stock, valued at approximately $58,602.10. The trade was a 41.63 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Precision BioSciences Price Performance

Shares of NASDAQ DTIL opened at $4.53 on Thursday. The firm has a market capitalization of $34.75 million, a P/E ratio of 75.51 and a beta of 1.59. The firm’s 50-day moving average price is $5.12 and its 200-day moving average price is $6.61. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. Precision BioSciences, Inc. has a 1-year low of $3.61 and a 1-year high of $15.97.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in DTIL. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Precision BioSciences by 22.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 15,534 shares of the company’s stock valued at $59,000 after acquiring an additional 2,805 shares in the last quarter. Commonwealth Equity Services LLC bought a new position in shares of Precision BioSciences in the 4th quarter worth $48,000. Samalin Investment Counsel LLC acquired a new stake in Precision BioSciences in the 4th quarter valued at $59,000. XTX Topco Ltd bought a new stake in Precision BioSciences during the 4th quarter valued at $67,000. Finally, Geode Capital Management LLC increased its stake in Precision BioSciences by 40.7% during the 3rd quarter. Geode Capital Management LLC now owns 65,974 shares of the company’s stock valued at $591,000 after purchasing an additional 19,088 shares in the last quarter. 37.99% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DTIL has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a research report on Wednesday, March 19th. BMO Capital Markets upgraded Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target on the stock in a report on Friday, January 10th.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.